Editas test CRISPR to treat beta-thalassemia & sickle cell disease
Category: #health  By Nikita Chaurasia  Date: 2019-06-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Editas test CRISPR to treat beta-thalassemia & sickle cell disease

Editas Medicine Inc., a U.S.-based pharmaceutical company recently announced results from trial of two different CRISPR-Cas9 genome editing strategies, one targeting the beta-globin locus and the other targeting the erythroid enhancer, for treatment of beta-thalassemia & sickle cell disease. The data was presented by the company at the 24th Congress of the European Hematology Association in Amsterdam, report sources.

For the record, Editas Medicine Inc., is a leading genome editing pharmaceutical company, that focus on potential of CRISPR-Cas9 & Cas12a genome editing strategies in treatment of patients with serious diseases. The company aims to develop, manufacture & commercialize durable, transformative precision genomic medicines for wide-ranging class of diseases.

Charles Albright, Chief Scientific Officer, Editas Medicine, was reported to say that the pre-clinical results validating cells edited at the beta-globin locus repopulated all lineages of the blood system including RBC precursors & the high percentage of fetal hemoglobin expression, showed potential to treat beta-thalassemia & sick cell disease. Editing at the site continues to meet the company’s pre-clinical goals for making the medicine for durable induction of fetal hemoglobin & maintaining normal hematopoietic stem cell function, Albright added.

In this study, NBSGW mice (supports engraftment of human hematopoietic stem cells without irradiation) were reportedly given an infusion of human CD34+ cells which were edited either at beta-globin locus or the BCL11Ae. In vivo-derived erythroid cells from BCL11Ae and edited CD34+ hematopoietic stem cells had increased non-productive indels and reduced total indels, as compared to other lineages that have been tested (a phenomenon not observed with beta-globin locus editing). Also, further optimization of guide RNA & nuclease combinations led to fetal hemoglobin expression of approximately 40% in the beta-globin, locus-edited erythroid cells.

Based on the data, the pharmaceutical company has initiated IND-enabling activities for an experimental CRISPR medicine, EDIT-301. The drug is designed to durably treat beta-thalassemia & sickle cell disease by editing the beta-globin locus, cite sources.

Source credits: http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-presents-pre-clinical-data-treatment-sickle-cell

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Chembio announces WHO Prequalification approval for HIV Self-Test
Chembio announces WHO Prequalification approval for HIV Self-Test
By Nikita Chaurasia

The test senses antibodies to HIV 1 and HIV 2, demonstrated specificity of 100% and sensitivity of 99.4%, when comparing amateur HIV self-test users to skilled professionals. Chembio Diagnostics, Inc., has reportedly announced that its SURE CHECK HI...

Amgen teams up with BeiGene to expand its oncology presence in China
Amgen teams up with BeiGene to expand its oncology presence in China
By Nikita Chaurasia

The pharmaceutical sector is often held accountable for treating the most crucial health conditions. The sector markets, innovates and produces those therapies which could become beneficial to patients on a larger scale. However, with increasing comp...

Aerospace company Erickson bags $996M SOF/PR Defense Contract
Aerospace company Erickson bags $996M SOF/PR Defense Contract
By Nikita Chaurasia

Erickson Inc., one of the leading aerospace and aerial services provider, has been providing best-in-class aviation services for national security, defense, MRO and manufacturing sectors for years. The company aims to offer high quality, efficient, i...